aibio
Company Updates ·
CNS Pharmaceuticals lays out oncology and neurology asset search
The July 2026 investor presentation describes a formal asset search after a $22.5 million financing and a leadership rebuild.
CNSP CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals (CNSP) news CNSP delisting and offering news
Latest CNS Pharmaceuticals news
- Financings
CNS Pharmaceuticals agrees to about $22.5 million private placement with pre-funded warrants
CNS Pharmaceuticals priced a private placement of common stock at $2.30 per share and pre-funded warrants at $2.299, for approximately $22.5 million gross. Most of the shares are pre-funded warrants for 9,143,479 shares. Closing is expected May 5, 2026. A director resigned and a new one was named.
- Listings
CNS Pharmaceuticals regains Nasdaq bid price compliance, faces one-year monitor
Nasdaq told CNS Pharmaceuticals on March 31, 2025 that it meets the $1.00 bid price rule. For one year, a new lapse leads to a delisting determination, with no compliance plan or extra time.
- Financings
CNS Pharmaceuticals increases its at-the-market stock program to $43.5 million
The company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025.
CNS Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $9.8 million | $9.3 million |
| Net income (loss) | -$15.9 million | -$14.9 million |
| Cash from operations | -$13.8 million | -$17.1 million |
| Cash and equivalents | $7.2 million | $6.5 million |
Questions about CNS Pharmaceuticals
Was CNS Pharmaceuticals delisted?
Our latest story on this, dated Mar 31, 2025: "CNS Pharmaceuticals regains Nasdaq bid price compliance, faces one-year monitor". The story links the filing or release it is based on. Read the story.
Has CNS Pharmaceuticals raised money recently?
Our latest story on this, dated May 4, 2026: "CNS Pharmaceuticals agrees to about $22.5 million private placement with pre-funded warrants". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of CNS Pharmaceuticals?
CNS Pharmaceuticals, Inc. trades under the ticker CNSP on NASDAQ.
Where is CNS Pharmaceuticals listed?
CNS Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of CNS Pharmaceuticals?
The SEC Central Index Key (CIK) for CNS Pharmaceuticals, Inc. is 1729427. Its filings are on SEC EDGAR.
How many shares does CNS Pharmaceuticals have outstanding?
1,461,449 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is CNS Pharmaceuticals listed under?
Our directory records CNS Pharmaceuticals, Inc. under United States.
What does CNS Pharmaceuticals do?
Our directory classifies CNS Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of CNS Pharmaceuticals?
The ISIN recorded for CNS Pharmaceuticals, Inc. is US18978H5081.
Does aibio.space cover CNS Pharmaceuticals?
aibio.space lists CNS Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is CNS Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as NV.
Is CNS Pharmaceuticals profitable?
CNS Pharmaceuticals, Inc. reported a net loss of $15.9 million for the fiscal year ended Dec 31, 2025, and used $13.8 million of cash in operations, per its annual report to the SEC.
How much does CNS Pharmaceuticals spend on research and development?
$9.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does CNS Pharmaceuticals have?
$20.0 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest CNS Pharmaceuticals (CNSP) stock news?
Our latest story on CNS Pharmaceuticals, dated Jul 2, 2026: "CNS Pharmaceuticals lays out oncology and neurology asset search". The July 2026 investor presentation describes a formal asset search after a $22.5 million financing and a leadership rebuild. Source.
Investor discussion: CNS Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,8.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Stock chart
SEC filings and registration
- SEC name
- CNS Pharmaceuticals, Inc.
- CIK
- 1729427
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- CNSP (Nasdaq)
- State or country of incorporation
- NV
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 2100 WEST LOOP SOUTH, HOUSTON, TX, 77027
- Phone
- 1-800-946-9185
- Shares outstanding
- 1,461,449 as of 2026-08-11 (10-Q filed 2026-08-12)
Recent filings
Listing details
- Company
- CNS Pharmaceuticals, Inc.
- Ticker
- CNSP
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US18978H5081
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction